T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.81B |
| 2 |
Boeing
BA
|
+$1.68B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.33B |
| 4 |
Amphenol
APH
|
+$1.11B |
| 5 |
CME Group
CME
|
+$902M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$3.65B |
| 2 |
Advanced Micro Devices
AMD
|
+$2.51B |
| 3 |
UnitedHealth
UNH
|
+$2.06B |
| 4 |
Uber
UBER
|
+$1.84B |
| 5 |
Adobe
ADBE
|
+$1.44B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.21% |
| 2 | Healthcare | 12.77% |
| 3 | Consumer Discretionary | 11.71% |
| 4 | Financials | 11.15% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2801
Emergent Biosolutions
EBS
$240M
| $113K | ﹤0.01% |
11,800
| – | – |
|
2802
The ONE Group
STKS
$56.2M
| $113K | ﹤0.01% |
38,790
| – | – |
|
2803
Latham Group
SWIM
$901M
| $111K | ﹤0.01% |
15,856
+2,168
| +16% | +$14.5K |
|
|
YMAB
2804
DELISTED
Y-mAbs Therapeutics
YMAB
| $111K | ﹤0.01% |
14,067
-8,470
| -38% | -$103K |
|
2805
MeiraGTx Holdings
MGTX
$1.26B
| $110K | ﹤0.01% |
17,976
+5,259
| +41% | +$30.8K |
|
|
TEAD
2806
Teads Holding Co
TEAD
$63.7M
| $110K | ﹤0.01% |
15,205
+1,855
| +14% | +$10.1K |
|
2807
Eve Holding
EVEX
$972M
| $109K | ﹤0.01% |
19,928
+7,919
| +66% | +$29.8K |
|
2808
Lightpath Technologies
LPTH
$868M
| $109K | ﹤0.01% |
30,800
+15,500
| +101% | +$28.9K |
|
2809
Children's Place
PLCE
$55.4M
| $107K | ﹤0.01% |
10,200
| – | – |
|
2810
Vanda Pharmaceuticals
VNDA
$314M
| $107K | ﹤0.01% |
22,265
+3,370
| +18% | +$16.2K |
|
2811
Resources Connection
RGP
$149M
| $105K | ﹤0.01% |
12,249
+1,863
| +18% | +$15.7K |
|
2812
Viemed Healthcare
VMD
$358M
| $105K | ﹤0.01% |
13,005
+1,997
| +18% | +$17.3K |
|
2813
Pixelworks
PXLW
$43.3M
| $104K | ﹤0.01% |
12,033
| – | – |
|
2814
Trevi Therapeutics
TRVI
$2.53B
| $104K | ﹤0.01% |
25,166
+6,119
| +32% | +$19.6K |
|
2815
Aemetis
AMTX
$126M
| $103K | ﹤0.01% |
38,016
+5,281
| +16% | +$16.6K |
|
2816
Orion Group Holdings
ORN
$398M
| $103K | ﹤0.01% |
+14,010
| New | +$101K |
|
2817
Mama's Creations
MAMA
$823M
| $101K | ﹤0.01% |
12,622
+2,073
| +20% | +$17.2K |
|
2818
Aquestive Therapeutics
AQST
$550M
| $99K | ﹤0.01% |
27,669
+3,821
| +16% | +$17.6K |
|
2819
ASP Isotopes
ASPI
$550M
| $99K | ﹤0.01% |
21,646
+2,757
| +15% | +$14.7K |
|
|
SRTA
2820
Strata Critical Medical Inc
SRTA
$534M
| $98K | ﹤0.01% |
22,853
+2,565
| +13% | +$9.77K |
|
|
PBPB
2821
DELISTED
Potbelly
PBPB
| $98K | ﹤0.01% |
+10,347
| New | +$93.9K |
|
2822
Lifezone Metals
LZM
$350M
| $97K | ﹤0.01% |
13,890
+2,203
| +19% | +$14.7K |
|
2823
Revolution Medicines Inc Warrant
RVMDW
$124M
| $97K | ﹤0.01% |
606,180
| – | – |
|
2824
Spruce Power Holding Corp
SPRU
$36M
| $97K | ﹤0.01% |
32,637
| – | – |
|
|
WOW
2825
DELISTED
WideOpenWest
WOW
| $97K | ﹤0.01% |
19,530
+2,657
| +16% | +$13.6K |
|
Similar funds
T. Rowe Price Associates's Q4 2024 Portfolio in Review
As of Q4 2024, T. Rowe Price Associates held 3,110 positions worth $867B, down 0.13% from $869B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
T. Rowe Price Associates's Q4 2024 filing shows 92 new, 1,805 increased, 946 reduced and 96 closed positions. Its largest new stake was South Bow Corp: 12,337,055 shares worth $291M. The largest sale was Apple, an estimated $3.65B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2024 buy was South Bow Corp: 12,337,055 shares worth $291M.
- T. Rowe Price Associates added most to Broadcom in Q4 2024, an estimated $2.81B increase.
- T. Rowe Price Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $3.65B.
- T. Rowe Price Associates fully exited Tempus AI in Q4 2024, selling an estimated $292M.
- T. Rowe Price Associates's ten largest holdings make up 35% of its $867B portfolio in Q4 2024.
- T. Rowe Price Associates opened 92 new positions and closed 96 in Q4 2024.
- T. Rowe Price Associates's portfolio value fell 0.13% quarter-over-quarter to $867B.
Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.